COX-2 Selective Furanone Crystalline Form Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional non-steroidal anti-inflammatory drugs (NSAIDs) inhibit both COX-1 and COX-2 enzymes, leading to gastrointestinal toxicities and limitations in clinical use, while selective COX-2 inhibitors aim to address this by providing anti-inflammatory effects without these toxicities, but they require improved physicochemical stability and formulation for effective oral pharmacological compositions.
Innovation Solution
A method for preparing 5-{4-(aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone with crystalline forms A or G, or a mixed form, ensuring excellent physicochemical stability, high dissolution rate, and uniform content, using a pharmaceutical composition including the furanone derivative, a pharmaceutically acceptable diluent, and lubricant, with specific particle size ranges to enhance stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional NSAIDs are used to inhibit COX-1 and COX-2, then anti-inflammatory efficacy is achieved, but gastrointestinal toxicities occur
Solution Approach 1:
The patent extracts and isolates the COX-2 inhibitory function from the dual COX-1/COX-2 inhibition mechanism of conventional NSAIDs. By designing selective COX-2 inhibitors that specifically target COX-2 enzyme without significantly affecting COX-1, the invention separates the therapeutic anti-inflammatory effect from the harmful gastrointestinal side effects, achieving efficacy while reducing toxicity.
Solution Approach 2:
The patent applies local quality by creating drugs with selective action on specific tissue targets. The COX-2 selective inhibitors are designed to preferentially inhibit COX-2 enzyme which is overexpressed in inflamed tissues, while sparing COX-1 in gastrointestinal tissues. This localized selective inhibition provides anti-inflammatory benefits at the site of inflammation without compromising gastrointestinal protection.
2Object-affected harmful factors
If selective COX-2 inhibitors are developed to reduce gastrointestinal toxicities, then gastrointestinal safety is improved, but physicochemical stability and formulation challenges arise
Solution Approach 1:
The patent employs parameter changes by systematically varying crystalline form parameters (polymorphism) to optimize physicochemical stability. Different crystalline forms of COX-2 inhibitors are characterized and selected based on their stability profiles, solubility characteristics, and bioavailability. By controlling crystalline structure parameters, the invention achieves enhanced physical and chemical stability while maintaining therapeutic efficacy.
Solution Approach 2:
The patent utilizes composite material approaches through pharmaceutical formulation development. Stable crystalline forms of COX-2 inhibitors are combined with appropriate excipients, diluents, and binding agents to create formulation composites that enhance overall stability, improve manufacturability, and ensure consistent bioavailability. The composite formulation approach addresses individual compound limitations through synergistic material combinations.
3Stability of the object's composition
If crystalline forms are optimized for stability, then product stability is enhanced, but dissolution rate and bioavailability must be maintained
Solution Approach 1:
The patent applies parameter changes by systematically evaluating and selecting crystalline forms based on multiple parameters including stability, dissolution rate, and bioavailability. Different polymorphic forms are characterized to identify optimal balance points where sufficient physical and chemical stability is achieved without compromising dissolution performance. This multi-parameter optimization enables selection of crystalline forms that satisfy both stability and dissolution requirements.
Data Source
AI summary
The present invention relates to a pharmaceutical composition including (i) as a major ingredient, a novel 5-{4-(Aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone compound (Formula 1) or a pharmaceutically acceptable salt thereof, which has a crystalline form A or G, or a mixed form thereof and has a 50% volume particle diameter (d(0.5)) of 3 μm to 9 μm and a 90% volume particle diameter (d(0.9)) of 10 μm to 50 μm, (ii) a pharmaceutically acceptable diluent, and (iii) a pharmaceutically acceptable lubricant. The pharmaceutical composition of the present invention has the advantages of good stability, high dissolution rate, improved content uniformity, and excellent pharmacokinetic properties. Due to these advantages, as a non-steroidal anti-inflammatory drug, the pharmaceutical composition of the present invention may be effective in treating inflammation or pain.